window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

multiple myeloma

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome

    Poolbeg Pharma has dosed the first patient in a clinical [...]

    July 13, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Poolbeg secures European patent decision for POLB 001 in cytokine release syndrome

    Poolbeg Pharma has received a decision to grant a European [...]

    June 16, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg begins patient recruitment for POLB 001 TOPICAL trial

    Poolbeg Pharma has activated the first clinical site and begun [...]

    June 11, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    SMC approves TALVEY for relapsed multiple myeloma in Scotland

    The Scottish Medicines Consortium (SMC) has accepted TALVEY (talquetamab) for [...]

    June 9, 2026
  • Clinical & Regulatory,Digital & Data,Therapeutic Areas

    Quest Diagnostics launches flow cytometry MRD blood test for myeloma to support ultrasensitive monitoring

    Quest Diagnostics has introduced a new blood-based test for measurable [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Talquetamab recommended by NICE for relapsed and refractory multiple myeloma

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Heidelberg Pharma sees complete remissions in HDP-101 multiple myeloma trial

    Heidelberg Pharma has reported further clinical activity from its Phase [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    CytoAgents receives fourth NIH grant to advance research on cytokine release syndrome in CAR T-cell therapy

    CytoAgents, a clinical-stage biotechnology company developing an oral small-molecule immune [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg secures free supply of bispecific antibody for POLB 001 trial at The Christie

    Poolbeg Pharma has appointed Accelerating Clinical Trials (ACT) to run [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Heidelberg Pharma advances dual ATAC pipeline, secures $20M payment and eyes 2027 funding runway

    Lead multiple myeloma candidate enters Cohort 8; second asset dosed [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • mRNA therapy shows potential for treating autoimmune diseases
    Categories: Drug Discovery & Development, Research & Development, Therapeutic Areas
  • Australian Phase 1 trial begins for CAR-T therapy targeting solid tumours
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • Atsena selects clinical candidate for Stargardt disease gene therapy
    Categories: Advanced Therapies, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top